Alopexx (ALPX) IPO deck
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).
![](/content/images/size/w1304/2023/02/fwp_img001-1.jpg)